AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06598410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: watching cartoon
Description: Children in this group will be shown a cartoon film 5 minutes before the procedure. They will continue to play the game during the procedure.
Study NCT06610591 — intervention group
Intervention type: PROCEDURE
Intervention: Achilles Lengthening Surgery
Description: The procedure is undertaken under general anaesthetic and involves horizontal hemi-section of the Achilles tendon via small 'stab' incisions at three levels to effect a lengthening of the tendon. The patient is then placed in a walking cast for four weeks thereafter. This surgery is usual care for most children with symptomatic ITW with plantarflexion contractures who have failed non-operative management.
Study NCT06611202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A multidisciplinary six-minute walking group intervention-spearheaded by physiotherapists, occupational therapists, and psychologists-in enhancing physical activity, mobility, cognitive function, and functional independence among patients with dementia.~Physiotherapy Component: A six-minute walking group will be conducted twice a week for 8 weeks, targeting improvements in mobility, endurance, and balance. Occupational Therapy Intervention: Occupational therapists will integrate functional tasks (Games and throwing of balls to court, bean bag target game to enhance exercise relevance to daily activities. A psychologist will provide mental health support during the sessions, utilising techniques like time focus reminiscence therapy to engage patients and reduce anxiety.
Study NCT06611202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: Medication on our dementia wards are being review during ward round and when needs arise. The medication management in drugs will be fully documented and accounted for in the course of the study.
Study NCT06623344 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging with or without Contrast
Description: Completion of Magnetic Resonance Imaging of the brain, heart, lungs, and liver with and without contrast.
Study NCT06623357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilot Training Protocol
Description: The pilot training protocol uses principles based on evidence-based research on factors that support caregiver learning of and adherence to home-therapy techniques/recommendations.
Study NCT06623357 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Training Protocol
Description: The standard training protocol uses the caregiver training methods that are currently used in our clinics.
Study NCT06692738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Administered intravenously (IV) on Day 1 of each 21-day cycle
Study NCT06692738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered intravenously (IV) on Day 1 of each 21-day cycle
Study NCT06692738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
Study NCT06692738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
Study NCT06692738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
Study NCT06692738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
Study NCT06692738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Administered intravenously (IV) on Days 1, 8, and 15 of each 21-day cycle up to 4 cycles
Study NCT06692738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Administered intravenously (IV) on Days 1, 8, and 15 of each 21-day cycle up to 4 cycles
Study NCT06728956 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: READY for MS UK digital programme
Description: Online self-directed programme supported by HCPs
Study NCT06729203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound cavitation
Description: Ultrasound Fat Cavitation (USFC) is the method in handling obesity, especially in destroying fat and shaping a particular part of the body. As one of the non-surgical correction methods, USFC is preferred at decreasing the risk of complications due to obesity.
Study NCT06729203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The female will stand on the cushioned tread and grasp by her both hands the two arms of the treadmill. Treadmill will adjust to apply moderate intensity training. It was used for 30 minutes divided into five-minutes warming up, twenty-minutes active exercise and five-minutes cooling down and it was used twice a week for twelve weeks.
Study NCT06729736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Description: The ERAS protocol includes:~* Pre-admission education, counselling and nutritional support~* Pre-induction oral analgesics~* Minimal fasting and carbohydrate loading~* Omission of nasogastric intubation~* Intra-operative abdominal nerve block~* Early mobilization~* Early oral nutrition and minimal IV fluids~* Multimodal opioid sparing analgesia~* Postoperative nausea and vomiting prophylaxis~* Early removal of urinary catheters
Study NCT06728696 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implant with with dual zone technique using concentrated growth factor graft.
Description: In the test group, pouch technique + CGFG will be used. The CGFG will be packed in the split-thickness labial pouch between the labial bone plate and the overlying gingiva of the extraction socket. A convenient blood sample will be withdrawn from a peripheral venous blood from the patient using a specialized vacutaine. A standard, disposable, 10-ml non- anticoagulant tube and a matching centrifuge device was used. To prepare the CGFG, the centrifuge is accelerated for 30 seconds, then centrifuged at 2700 rpm for 2 minutes, 2400 rpm for 4 minutes, 2700 rpm for 4 minutes, and 3000 rpm for 3 minutes before being decelerated for 36 seconds to stop.
Study NCT06728696 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant with dual zone technique using connective tissue graft.
Description: Patients assigned to the control group will receive pouch technique + CTG. Following implant placement, a split-thickness labial pouch between the labial bone plate and the overlying gingiva of the extraction socket will be performed using 15c mini blade to allow for the placement of a CTG. The pouch preparation will be extended apical beyond the muco-gingival junction and to the neighboring teeth mesiodistally. The CTG will be harvested from the palate with a thickness of 1.5 mm using single-incision technique, which was done approximately 2-3 mm apical to the gingival margin of the maxillary teeth and parallel to the palatal long axis. A resorbable suture will be used to first pierce the labial mucosa along with the periosteum at an apical part, which then exits from the sulcus. Afterward, the CTG will be tucked in the pouch, labial to the suture, and held at a coronal area by using the needle to pierce it from its inner surface toward the labial soft tissue. The knot will then be se
Study NCT06728059 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automated Insulin Delivery Adaptive NETwork (AIDANET)
Description: Group A participants will use the AIDANET system at home for 7 days/6 nights. They will continue use of AIDANET system for 18 hours during the hotel session and then use AIDANET+BPS_RL for 18 hours during the hotel session.
Study NCT06728059 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AIDANET+ BPS_RL→AIDANET
Description: Group B participant will use the AIDANET+BPS_RL system for 18 hours during the hotel session and will then use AIDANET system for 18 hours during the hotel session. They will continue to use AIDANET+BPS_RL system at home for 7 days/6 night and then use the AIDANET system at home for 7 days/6 nights.
Study NCT06727617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: intravenous infusion of 300 mg, administered every 3 weeks as one cycle, on the first day of each cycle, with a maximum treatment duration of 2 years (up to 35 treatment cycles)
Study NCT06727617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cisplatin: Administered by intravenous infusion during concurrent chemoradiotherapy at a dose of 30-40 mg/m² once weekly for only 5-6 treatment cycles; during sequential chemoradiotherapy, administered at 60-75 mg/m² on the first and second days of each cycle, once every 3 weeks (21 days) for only 4 treatment cycles.~Paclitaxel: Nab-paclitaxel administered by intravenous infusion at a dose of 135-175 mg/m² on the first day of each cycle, once every 3 weeks (21 days) for only 4 treatment cycles.
Study NCT06727617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Cisplatin: Administered by intravenous infusion during concurrent chemoradiotherapy at a dose of 30-40 mg/m² once weekly for only 5-6 treatment cycles; during sequential chemoradiotherapy, administered at 60-75 mg/m² on the first and second days of each cycle, once every 3 weeks (21 days) for only 4 treatment cycles.~Paclitaxel: Nab-paclitaxel administered by intravenous infusion at a dose of 135-175 mg/m² on the first day of each cycle, once every 3 weeks (21 days) for only 4 treatment cycles.
Study NCT06727617 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Pelvic external beam radiation therapy at a dose of 1.8 Gy per fraction or 2 Gy per day, 5 times per week, with a total dose of 45-50 Gy.
Study NCT06727617 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy
Description: Pelvic external beam radiation therapy at a dose of 1.8 Gy per fraction or 2 Gy per day, 5 times per week, with a total dose of 45-50 Gy.
Study NCT06728215 — intervention group
Intervention type: DEVICE
Intervention: CRET 1
Description: Fisiowarm 7.0 and the new capacitive/resistive electrode, for 15' at a frequency of 300 KHz (Treated Group).
Study NCT06728215 — intervention group
Intervention type: DEVICE
Intervention: CRET 2
Description: Classical methodology using the monopolar electrode Activ CT8 INDIBA® at a frequency of 448 KHz in both resistive and capacitive modes, for 10 min each mode with two different electrodes. (Control group).
Study NCT05746208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given orally
Study NCT05746208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05746208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate
Description: Given IV
Study NCT06544512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive relaxation exercise
Description: looking at pain and anxiety by practicing progressive relaxation exercises
Study NCT05651828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vismodegib 150 MG Oral Capsule
Description: Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.
Study NCT05651828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib 150 MG Oral Capsule
Description: Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.
Study NCT05812820 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LiveSpo DIA30
Description: LiveSpo® DIA 30 has a registration number: 6547/2019/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam
Study NCT05812820 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LiveSpo CLAUSY
Description: LiveSpo® CLAUSY has a registration number: 4071/2021/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam
Study NCT05812820 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: RO
Description: Aquafina's distilled water and reverse osmosis (RO) water, produce by PepsiCo, have both obtained ISO 9001:2015 and ISO 22000:2018 certifications, which are internationally recognized standards for quality management and food safety management systems, respectively.~The RO water ampoules are produced using a similar process as the LIVESPO DIA30/CLAUSY but contain 5ml of high-quality distilled water from Aquafina in an opaque plastic bottle
Study NCT01446120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH-Insulin Injection
Study NCT01446120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin loaded Orally Dissolved Films (insulin-ODF
Study NCT05873478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: The HIIT sessions ranging from 4-12 minutes in duration for 8 weeks in which three sessions will be conducted each week (weeks 1-3: 4 minutes; weeks 4-6: 8 minutes; weeks 7-8: 12 minutes respectively), with a work to rest ratio of 30sec: 10sec, as mention in table 1. Experimental group/HIT group engaged in their HIIT sessions (inclusive of a short warm-up activity including dynamic exercises i.e., walking/running, 8-10 minutes of HIIT and cool down which include static exercises i.e., shoulder and hip muscle stretches). Session duration and intensity are increased with weekly progression in intervention groups. The high resistance training sessions was be delivered by the researcher to HIT group
Study NCT05588258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Participants were given the 10% urea cream purchased in pharmacy or supermarket as appropriate after randomisation and their foot skin quality was assessed by validated questionnaire.
Description: Participants agreed to the interventions after allocation to each arm according to randomisation and after signing an informed consent form. The creams tested in this study provided to participants are authorised for sale within the European Union but are not considered drugs or medical devices. The main purpose of the interventions was based on the care and assessment of the quality of the skin of the participants' feet.
Study NCT05717998 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05717998 — intervention group
Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo cardiac PET/CT
Study NCT05717998 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging of the Heart
Description: Undergo CMR
Study NCT05717998 — intervention group
Intervention type: PROCEDURE
Intervention: Positron Emission Tomography
Description: Undergo cardiac PET/CT
Study NCT04891172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti COVID 19 Intravenous Immunoglobulin (C-IVIG)
Description: Intervention arm will receive single dose of 0.15g/kg C-IVIG. This will be infused within period of 16 hours intravenously. Additionally, all participants will receive same standard care.~Standard Care as per hospital protocol, which may include:~Airway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics, anti coagulant
Study NCT04892069 — intervention group
Intervention type: DRUG
Intervention: Insulin Degludec/Insulin Aspart
Description: All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in Lebanon. Decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Study NCT05182944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A：non-pCR patients
Description: After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（2-4 cycles Camrelizumab+Albumin Paclitaxel+Cisplatin and Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication
Study NCT05182944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B：non-pCR patients
Description: After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication
Study NCT05182944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A：pCR patients
Description: After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication
Study NCT05182944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B：pCR patients
Description: After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Best Supportive Care）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication
Study NCT05043740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repatha or Praluent
Description: Evolocumab (Repatha®) 140 mg or Alirocumab (Praluent) 75mg every two weeks, first subcutaneous injection at the time of randomization, followings during 12 months
Study NCT04956211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal therapy
Description: Patients will receive a standard regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one or two sessions within 2 days) with curettes and ultrasonic instruments.
Study NCT04956211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal therapy
Description: Patients will receive a standard regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one or two sessions within 2 days) with curettes and ultrasonic instruments.
Study NCT06290986 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pyrocardan® implant
Description: Biconcave-shaped CMC-1 interposition implant
Study NCT06290986 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligament reconstruction and tendon interposition (LRTI)
Description: Weilby slightly modified as described by Burton and Pellegrini
Study NCT05180331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application to Prevent Suicide (MAPS)
Description: Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
Study NCT05550545 — intervention group
Intervention type: OTHER
Intervention: cohort study
Description: Please note that this is an observational study; not applicable
Study NCT04533178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: soft spinal brace
Description: Use of a soft spinal brace 16 hours per day during the 6 week treatment period.
Study NCT04533178 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resting from all sports activities
Description: Resting from all sports activities
Study NCT04533178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resting from all sports activities
Description: Resting from all sports activities
Study NCT05116553 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SDT
Description: Standard 2 SDT (Self Determination Theory) psychological interviews.
Study NCT05116553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SDT
Description: Standard 2 SDT (Self Determination Theory) psychological interviews.
Study NCT05116553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APP + CA
Description: An APP with a CA (Conversational Agent).
Study NCT06071416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral sinus floor augmentation
Description: maxillary sinus floor augmentation by lateral approach
Study NCT06071416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic Calcium Phosphate
Description: appliaction of BCP bone substitute
Study NCT06071416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injectable platlets rich fibrin
Description: centrifuge 10 ml of patient blood to get I-PRF that applied to the bone substitute
Study NCT04621331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: HIF-PH inhibitor for treatment of anemia in CKD
Study NCT04861142 — intervention group
Intervention type: DRUG
Intervention: Anti-osteoporotic medication( alendronate or denosumab)
Description: Initiation of anti-osteoporotic medication (alendronate or denosumab)